Jerald Korn serves as General Counsel, Corporate Secretary of the Company. Prior to joining us, Mr. Korn served in various roles at TESARO, Inc. from April 2015 to July 2019, including General Counsel and Chief Administrative Officer, Global Chief Compliance Officer and Deputy General Counsel, and Assistant General Counsel and Compliance Officer. Prior to TESARO, Mr. Korn served as Associate General Counsel at Cubist Pharmaceuticals from August 2013 to March 2015, as Deputy Chief Compliance Officer at Millennium Pharmaceuticals from July 2011 to August 2013 and as Associate General Counsel and Compliance Officer at AMAG Pharmaceuticals from August 2008 to July 2011. Prior to AMAG Pharmaceuticals, he was an associate in the law firm of Ropes & Gray LLP.
As the General Counsel a Corporate Secretary of Kaleido Biosciences Inc, the total compensation of Jerald Korn at Kaleido Biosciences Inc is $1,505,420. There are no executives at Kaleido Biosciences Inc getting paid more.
Jerald Korn is 41, he's been the General Counsel a Corporate Secretary of Kaleido Biosciences Inc since 2019. There are 16 older and 1 younger executives at Kaleido Biosciences Inc. The oldest executive at Kaleido Biosciences Inc is Anne Prener, 62, who is the Independent Director.
Jerald's mailing address filed with the SEC is C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE, MA, 02139.
Over the last 6 years, insiders at Kaleido Biosciences Inc have traded over $0 worth of Kaleido Biosciences Inc stock and bought 3,273,186 units worth $32,952,342 . The most active insiders traders include Ventures Fund Iv General Pa..., Joshua T Brumm a Ventures Fund V General Par.... On average, Kaleido Biosciences Inc executives and independent directors trade stock every 119 days with the average trade being worth of $55. The most recent stock trade was executed by Daniel L Menichella on 8 February 2021, trading 20,000 units of KLDO stock currently worth $230,000.
the next breakthrough microbiome company from flagship venturelabs – the innovation foundry of flagship ventures – is coming.
Kaleido Biosciences Inc executives and other stock owners filed with the SEC include: